According to Portage Biotech's latest financial reports the company has a price-to-book ratio of 0.1593.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 1.15 | 114.23% |
2022-12-31 | 0.5363 | -35.74% |
2021-12-31 | 0.8345 | -46.43% |
2020-12-31 | 1.56 | 123.06% |
2019-12-31 | 0.6983 | -76.76% |
2018-12-31 | 3.00 | 232.32% |
2017-12-31 | 0.9041 | 8.77% |
2016-12-31 | 0.8312 | -75.96% |
2015-12-31 | 3.46 | -41% |
2014-12-31 | 5.86 | -27.27% |
2013-12-31 | 8.06 | 394.4% |
2012-12-31 | 1.63 | 156.12% |
2011-12-31 | 0.6364 | -64.39% |
2010-12-31 | 1.79 | -35.43% |
2009-12-31 | 2.77 | 18.19% |
2008-12-31 | 2.34 | 67.3% |
2007-12-31 | 1.40 | -2.14% |
2006-12-31 | 1.43 | 2.81% |
2005-12-31 | 1.39 | -83.39% |
2004-12-31 | 8.38 | 67.4% |
2003-12-31 | 5.00 | -307.49% |
2002-12-31 | -2.41 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | -6.34 | -4,083.71% | Bahamas |
NRC Health
NRC | 15.1 | 9,412.24% | ๐บ๐ธ USA |